在小鼠中,Vγ6/Vδ1 + γδ T 细胞可以保护血管新生素 II 对血压和内皮功能的影响
Ahmad U M Mahmoud1, Antoine Caillon1, Brandon Shokoples1
1Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research.
Journal of hypertension
|September 9, 2024
概括
玛三角 (γδ) T 细胞,特别是Vγ6/Vδ1+ γδ T 细胞,可以防止血管新生素II诱导的高血压和血管问题. 准这些细胞可能为血压调节提供新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管生物学 心血管生物学
- T细胞生物学T细胞生物学
背景情况:
- 马三角 (γδ) T 细胞与血管激素II (AngII) 诱导的高血压和血管损伤有关.
- 在 γδ T 细胞上的特定 T 细胞受体 (TCR) 变量 (V) γ 链决定了它们的组织迁移和功能.
- 在AngII介导的高血压期间,围血管组织中特定的γδ T细胞亚型的作用尚不清楚.
研究的目的:
- 调查假设,围血管组织中的特定 γδ T 细胞 Vγ 亚型中介于 AngII 诱导的高血压效应.
- 为了确定对AngII输液的反应中γδ T细胞Vγ亚型的分布和激活状态.
- 评估Vγ6和Vγ4 γδ T细胞对AngII诱导的高血压和血管功能障碍的功能影响.
主要方法:
- 在C57BL/6J小鼠中输注 ангиотензинII (AngII),以诱导高血压.
- 在和周血管组织 (下降胸前大动脉和中腔血管) 中对γδ T细胞Vγ亚型的流细胞测量分析.
- 管理或抗Vγ6 / Vγ4抗体以中和特定的γδ T细胞群体;评估血压,中腔动脉功能和重塑.
主要成果:
- Vγ6/Vδ1+ γδ T 细胞是周血管脂肪组织 (PVAT) 中的主导亚型,并被AngII增加.
- AngII输液导致周血管组织中Vγ6/Vδ1+ γδ T 细胞的激活增加.
- 对Vγ6/Vδ1+ γδ T细胞的中和加剧了AngII诱导的血压升高和内皮功能障碍,而Vγ4+ T细胞枯竭没有影响.
结论:
- Vγ6/Vδ1+ γδ T 细胞通过减少由AngII引起的血压升高和内皮功能障碍来发挥保护作用.
- 这些发现突出了围血管组织中特定的γδ T 细胞子集作为AngII诱导血管反应的关键调解者.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
Antihypertensive Drugs: Direct Renin Inhibitors
510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510
Antihypertensive Drugs: Action of β1 Blockers
320
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
320
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398


